TECH - Bio-Techne Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
163.05
+1.64 (+1.02%)
At close: 4:00PM EST

163.05 0.00 (0.00%)
After hours: 4:32PM EST

Stock chart is not supported by your current browser
Previous Close161.41
Open160.41
Bid0.00 x 200
Ask0.00 x 1000
Day's Range159.69 - 164.87
52 Week Range125.27 - 206.04
Volume209,077
Avg. Volume252,641
Market Cap6.158B
Beta (3Y Monthly)1.47
PE Ratio (TTM)48.98
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.28 (0.75%)
Ex-Dividend Date2018-11-08
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire14 days ago

    Report: Exploring Fundamental Drivers Behind Equity Lifestyle Properties, AvalonBay Communities, Kadant, Mastercard, Bio-Techne, and Erie Indemnity — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Nov. 02, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • PR Newswire17 days ago

    Bio-Techne Declares Dividend

    MINNEAPOLIS , Oct. 30, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended September ...

  • PR Newswire17 days ago

    Bio-Techne Releases First Quarter Fiscal 2019 Results

    MINNEAPOLIS , Oct. 30, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the first quarter ended September 30, 2018 . First Quarter FY2019 Snapshot First ...

  • Bio-Techne To Present At The 2018 Stephens NY Investment Conference
    PR Newswire20 days ago

    Bio-Techne To Present At The 2018 Stephens NY Investment Conference

    MINNEAPOLIS , Oct. 26, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the 2018 Stephens NY Investment ...

  • PR Newswirelast month

    Bio-Techne Signs Strategic Cooperation Agreement with Micropoint Bioscience

    MINNEAPOLIS, Oct. 12, 2018 /PRNewswire/ -- Bio-Techne has entered into a strategic cooperation agreement with Micropoint Bioscience of Shenzhen, China. Chuck Kummeth, President and CEO of Bio-Techne, Yan Pingyi, Chairman of Micropoint Bioscience, and Wang Bin, Executive Vice President, Shenzhen Association of Medical Devices, all attended the meeting and signing ceremony. Micropoint Bioscience is a high-tech, newly-listed enterprise in China that has developed a microfluidic diagnostic chip for point-of-care (POC) testing.

  • PR Newswirelast month

    Bio-Techne To Host Conference Call On October 30, 2018 To Announce First Quarter 2019 Financial Results

    MINNEAPOLIS , Oct. 11, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call on Tuesday, October 30, 2018 at 8:00 a.m. CDT to review first ...

  • Bio-Techne Scientist Presented with the CASSS CE Pharm Award
    PR Newswirelast month

    Bio-Techne Scientist Presented with the CASSS CE Pharm Award

    MINNEAPOLIS , Oct. 2, 2018 /PRNewswire/ -- Bio-Techne is proud to announce that one of its Principal Scientists, Jiaqi Wu , Ph.D., was presented with the CE Pharm Award at this year's CE Pharm meeting ...

  • PR Newswire2 months ago

    Bio-Techne Announces Cell and Gene Therapy Initiative

    MINNEAPOLIS, Sept. 27, 2018 /PRNewswire/ -- Bio-Techne, a global leader of research and manufacturing-grade reagents, has announced a corporate initiative to advance cell and gene therapy research and ex vivo cell processing. Through strategic acquisitions and internal scientific innovation, Bio-Techne has become uniquely positioned to provide a comprehensive, innovative, and flexible set of reagents and instrumentation across the cell and gene therapy workflow. Bio-Techne's solutions for the cell therapy workflow span its portfolio, including GMP-grade cytokines and growth factors, high-quality antibodies for flow cytometry and immunocytochemical characterization, gold-standard immunoassays and next-generation automated immunoassay platforms, DNA and RNA in situ hybridization (ISH) assays, GMP-grade small molecules, and more.

  • PR Newswire2 months ago

    Bio-Techne Supports International Antibody Validation Meetings

    MINNEAPOLIS, Sept. 19, 2018 /PRNewswire/ -- Bio-Techne is proud to be sharing its 30+ years of industry leading expertise in antibody development and validation from its R&D Systems and Novus Biologicals brands at the 3rd International Antibody Validation Meeting on September 20-21, 2018. Leading researchers from academia, the biopharma industry, and antibody developers will gather to discuss best practices in research antibody validation with the goal of improving validation standards and enhancing research reproducibility. Birte Aggeler, Ph.D., Director of Antibody Development and Flow Cytometry at Bio-Techne, will present results from Bio-Techne's newest approaches to antibody validation, including the company's initiative to use CRISPR gene editing technology to validate antibodies in knockout (KO) cell lines.

  • PR Newswire2 months ago

    Bio-Techne Announces Publication of Data Demonstrating Additional Clinical Validation of its EPI Test in European Urology Journal

    MINNEAPOLIS , Sept. 18, 2018 /PRNewswire/ -- Bio-Techne today announced the online publication of its second prospective US clinical validation study of the Exosome Diagnostics-branded ExoDx® Prostate(IntelliScore) ...

  • Bio-Techne Fills a Need for Simple Tools to Study Glycobiology
    PR Newswire2 months ago

    Bio-Techne Fills a Need for Simple Tools to Study Glycobiology

    MINNEAPOLIS, Sept. 6, 2018 /PRNewswire/ -- Bio-Techne researchers publish papers that promise to open the field of glycobiology to the masses. This modification of proteins is called glycosylation. Because glycans have been tied to many pathologies, ranging from cancer to neurodegenerative disease, it is important to better understand their structures and functions.

  • Bio-Techne To Present At The Morgan Stanley 16th Annual Global Healthcare Conference
    PR Newswire2 months ago

    Bio-Techne To Present At The Morgan Stanley 16th Annual Global Healthcare Conference

    MINNEAPOLIS , Sept. 5, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the Morgan Stanley 16 th Annual ...

  • Bio-Techne To Present At The Baird 2018 Global Healthcare Conference
    PR Newswire3 months ago

    Bio-Techne To Present At The Baird 2018 Global Healthcare Conference

    MINNEAPOLIS , Aug. 28, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the Baird 2018 Global Healthcare ...

  • PR Newswire3 months ago

    Bio-Techne Introduces GMP Small Molecules for Stem Cell Therapy Development

    MINNEAPOLIS, Aug. 8, 2018 /PRNewswire/ -- Bio-Techne has introduced a new range of Tocris Bioscience-branded stem cell research compounds produced to cGMP standards, which are suitable for use as ancillary materials in the development of stem cell therapies. Bio-Techne has a highly-qualified team who have full control over the cGMP process, meaning we can ensure: a quality assured manufacturing system, guaranteed batch-to-batch consistency, traceability from starting material to final product, and consistency of supply. GMP compounds are synthesized in accordance with relevant sections of ICH Q7 guidelines, and are classified as tier 2 risk in the USP guidelines.

  • PR Newswire3 months ago

    Bio-Techne Declares Dividend

    MINNEAPOLIS , Aug. 7, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended June 30, 2018 ...

  • ACCESSWIRE3 months ago

    Bio-Techne Corporation to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Bio-Techne Corporation (NASDAQ: TECH ) will be discussing their earnings results in their Q4 Earnings Call to be held on August 7, 2018 at 9:00:00 AM Eastern ...

  • PR Newswire3 months ago

    Bio-Techne Releases Fourth Quarter Fiscal 2018 Results

    MINNEAPOLIS , Aug. 7, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the fourth quarter ended June 30, 2018 . Fourth Quarter and Full Year FY2018 Snapshot ...

  • PR Newswire3 months ago

    Bio-Techne Announces 2018 Investor Day And Webcast

    MINNEAPOLIS , Aug. 2, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host its 2018 Investor Day on Friday, September 7, 2018 , starting at 9:00 a.m. EDT ...

  • PR Newswire3 months ago

    Bio-Techne Corporation Completed Its Acquisition of Exosome Diagnostics, Inc.

    MINNEAPOLIS, Aug.1, 2018 /PRNewswire/ -- Bio-Techne Corporation (TECH) today announced it has completed its acquisition of Exosome Diagnostics, Inc. The transaction consideration includes an upfront payment of $250 million plus an additional $325 million that can be maximally earned through calendar year 2022 upon reaching certain performance milestones. With this acquisition, Minneapolis-based Bio-Techne now has a world-wide workforce in excess of 2,100 and has expanded its global reach with subsidiaries in every major geographic market. This acquisition continues to build on Bio-Techne's strategy to expand its market reach beyond its legacy research market into the liquid biopsy diagnostic arena with the introduction of Exosome Diagnostics' non-invasive prostate molecular test (EPI) to help physicians better serve their patients when considering the need for a prostate biopsy.

  • PR Newswire4 months ago

    Bio-Techne Introduces New Member of the Simple Western™ Family, with IR/NIR Detection Capabilities

    MINNEAPOLIS , July 24, 2018 /PRNewswire/ -- Bio-Techne again disrupts protein analysis technology with the introduction of the newest member of their ProteinSimple-branded Simple Western family, Jess. ...

  • PR Newswire4 months ago

    Bio-Techne To Host Conference Call On August 7, 2018 To Announce Fourth Quarter 2018 Financial Results

    MINNEAPOLIS , July 12, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call on Tuesday, August 7, 2018 at 8:00 a.m. CDT to review fourth ...

  • Bio-Techne Scales Antibody Validation Initiative Using CRISPR Gene Editing Technology Across a Broad Spectrum of Targets
    PR Newswire4 months ago

    Bio-Techne Scales Antibody Validation Initiative Using CRISPR Gene Editing Technology Across a Broad Spectrum of Targets

    Knockout Validation of Antibodies Confirms Specificity and Ensures Reproducible Results MINNEAPOLIS , July 10, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a family of brands with a unique ...

  • Bio-Techne Expands RNAscope® Assay Services Portfolio to Shorten Development Times and Save Costs
    PR Newswire5 months ago

    Bio-Techne Expands RNAscope® Assay Services Portfolio to Shorten Development Times and Save Costs

    MINNEAPOLIS, June 26, 2018 /PRNewswire/ -- Bio-Techne has added new capabilities and options to its Advanced Cell Diagnostics (ACD)-branded RNAscope® and BaseScope™ in situ hybridization (ISH) Assay Services Portfolio to improve biotech and pharma discovery timelines and costs. Responding to customer needs, the company has expanded its pre-validated tissue bank with new tissues and disease types and created pre-collected immuno-oncology datasets, profiling key targets and immune checkpoint markers.

  • PR Newswire5 months ago

    Bio-Techne To Acquire Exosome Diagnostics, Inc.

    MINNEAPOLIS and WALTHAM, Mass., June 25, 2018 /PRNewswire/ -- Bio-Techne Corporation (TECH) announced today that it has reached agreement to acquire Exosome Diagnostics, Inc. for $250 million in cash plus contingent consideration of up to $325 million due upon the achievement of certain future milestones. The transaction is expected to close in July or early August 2018. The transaction will be financed through a combination of cash on hand and a revolving line of credit facility that Bio-Techne expects to obtain prior to the closing of the acquisition.